We are live on
!
Find out more
MCM
M28 Capital Management Portfolio holdings
AUM
$53.8M
1-Year Est. Return
28.63%
This Fund
S&P 500
This Quarter
Est. Return
+59.95%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$105M
AUM Growth
+$9.12M
(+9.5%)
Cap. Flow
-$3.47M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
95.3%
Holding
17
New
5
Increased
2
Reduced
4
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$5.31M |
| 2 |
Arrowhead Research
ARWR
|
+$4.77M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$2.71M |
| 4 |
SLN
Silence Therapeutics
SLN
|
+$1.91M |
| 5 |
Atara Biotherapeutics
ATRA
|
+$1.83M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wave Life Sciences
WVE
|
+$9.58M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$4.27M |
| 3 |
VERV
Verve Therapeutics
VERV
|
+$3.01M |
| 4 |
CYPH
Cypherpunk Technologies Inc
CYPH
|
+$2.35M |
| 5 |
TG Therapeutics
TGTX
|
+$1.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Wave Life Sciences
WVE
$1.12B
| $41.3M | 39.39% |
5,903,405
-2,078,799
| -26% | -$9.58M |
|
2
Rocket Pharmaceuticals
RCKT
$348M
| $14.1M | 13.47% |
722,080
+56,200
| +8% | +$1.03M |
|
3
Invivyd
IVVD
$180M
| $13.9M | 13.22% |
9,248,250
| – | – |
|
4
ProQR Therapeutics
PRQR
$243M
| $7.07M | 6.74% |
1,910,600
+908,800
| +91% | +$1.19M |
|
|
5
Arrowhead Research
ARWR
$12.1B
| $5.84M | 5.56% |
+143,900
| New | +$4.77M |
|
|
6
Ionis Pharmaceuticals
IONS
$9.35B
| $4.77M | 4.55% |
+126,300
| New | +$5.31M |
|
7
Stoke Therapeutics
STOK
$1.82B
| $4.46M | 4.25% |
482,890
-39,660
| -8% | -$412K |
|
8
BridgeBio Pharma
BBIO
$16.5B
| $3.19M | 3.04% |
419,000
-94,300
| -18% | -$903K |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $2.86M | 2.72% |
+109,900
| New | +$2.71M |
|
10
Curis
CRIS
$9.53M
| $2.47M | 2.35% |
11,205
| – | – |
|
|
SLN
11
Silence Therapeutics
SLN
$521M
| $2.22M | 2.12% |
+145,900
| New | +$1.91M |
|
|
12
Atara Biotherapeutics
ATRA
$71.2M
| $1.44M | 1.37% |
+17,572
| New | +$1.83M |
|
|
13
TG Therapeutics
TGTX
$8.58B
| $1.24M | 1.18% |
104,400
-234,400
| -69% | -$1.7M |
|
|
NEXI
14
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $32.4K | 0.03% |
5,338
| – | – |
|
|
CYPH
15
Cypherpunk Technologies Inc
CYPH
$66.2M
| – | – |
-266,440
| Closed | -$2.35M |
|
|
VERV
16
DELISTED
Verve Therapeutics
VERV
| – | – |
-87,600
| Closed | -$3.01M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-61,200
| Closed | -$4.27M |
|
Similar funds
NCM
WEO
MML
CAM
ETCM
AA
TP
GMEI
M28 Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, M28 Capital Management held 17 positions worth $105M, up 9.5% from $95.8M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
M28 Capital Management withdrew a net $3.47M in Q4 2022, closing 3 positions and reducing 4 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $4.27M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.
Against the trend, M28 Capital Management opened a new position in Ionis Pharmaceuticals worth $4.77M.
- M28 Capital Management's largest Q4 2022 buy was Ionis Pharmaceuticals: 126,300 shares worth $4.77M.
- M28 Capital Management added most to ProQR Therapeutics in Q4 2022, an estimated $1.19M increase.
- M28 Capital Management's biggest Q4 2022 reduction was Wave Life Sciences, cutting an estimated $9.58M.
- M28 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $4.27M.
- M28 Capital Management's ten largest holdings make up 95% of its $105M portfolio in Q4 2022.
- M28 Capital Management opened 5 new positions and closed 3 in Q4 2022.
- M28 Capital Management's portfolio value rose 9.5% quarter-over-quarter to $105M.
Based on M28 Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.